Exposing drug industry funding of UK patient organisations

Drug company payment disclosures have limited transparency, but Piotr Ozieranski and colleagues find that they are increasing in value and are targeted at select patient organisations

Detalles Bibliográficos
Autores principales: Ozieranski, Piotr, Rickard, Emily, Mulinari,, Shai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2019
Materias:
Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529850/
https://www.ncbi.nlm.nih.gov/pubmed/31122928
http://dx.doi.org/10.1136/bmj.l1806
_version_ 1783420497561649152
author Ozieranski, Piotr
Rickard, Emily
Mulinari,, Shai
author_facet Ozieranski, Piotr
Rickard, Emily
Mulinari,, Shai
author_sort Ozieranski, Piotr
collection PubMed
description Drug company payment disclosures have limited transparency, but Piotr Ozieranski and colleagues find that they are increasing in value and are targeted at select patient organisations
format Online
Article
Text
id pubmed-6529850
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-65298502019-06-07 Exposing drug industry funding of UK patient organisations Ozieranski, Piotr Rickard, Emily Mulinari,, Shai BMJ Analysis Drug company payment disclosures have limited transparency, but Piotr Ozieranski and colleagues find that they are increasing in value and are targeted at select patient organisations BMJ Publishing Group Ltd. 2019-05-22 /pmc/articles/PMC6529850/ /pubmed/31122928 http://dx.doi.org/10.1136/bmj.l1806 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Analysis
Ozieranski, Piotr
Rickard, Emily
Mulinari,, Shai
Exposing drug industry funding of UK patient organisations
title Exposing drug industry funding of UK patient organisations
title_full Exposing drug industry funding of UK patient organisations
title_fullStr Exposing drug industry funding of UK patient organisations
title_full_unstemmed Exposing drug industry funding of UK patient organisations
title_short Exposing drug industry funding of UK patient organisations
title_sort exposing drug industry funding of uk patient organisations
topic Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529850/
https://www.ncbi.nlm.nih.gov/pubmed/31122928
http://dx.doi.org/10.1136/bmj.l1806
work_keys_str_mv AT ozieranskipiotr exposingdrugindustryfundingofukpatientorganisations
AT rickardemily exposingdrugindustryfundingofukpatientorganisations
AT mulinarishai exposingdrugindustryfundingofukpatientorganisations

Ejemplares similares